Monopar Therapeutics Files 8-K

Ticker: MNPR · Form: 8-K · Filed: 2024-08-14T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Monopar filed a standard 8-K, no major news.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on August 14, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates routine corporate reporting by Monopar Therapeutics, without disclosing new material events or financial performance details.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain information that suggests an immediate change in risk for investors.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is August 14, 2024.

In which state was Monopar Therapeutics Inc. incorporated?

Monopar Therapeutics Inc. was incorporated in Delaware.

What is the principal executive office address for Monopar Therapeutics Inc.?

The principal executive office address is 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091.

Does this filing disclose any specific new material events or financial results?

No, this filing primarily serves as a routine report for Regulation FD Disclosure and Financial Statements and Exhibits, without detailing specific new material events or financial results.

From the Filing

0001437749-24-026563.txt : 20240814 0001437749-24-026563.hdr.sgml : 20240814 20240814080010 ACCESSION NUMBER: 0001437749-24-026563 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240814 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240814 DATE AS OF CHANGE: 20240814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241204237 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20240812_8k.htm FORM 8-K mnpr20240812_8k.htm false 0001645469 0001645469 2024-08-14 2024-08-14     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 14, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 7.01   Regulation FD Disclosure.     On August 14, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted imaging radiopharmaceutical MNPR-101-Zr.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release Dated August 14, 2024 104   Cover Page Interactive Data File (embedded

View on Read The Filing